Mesenchymal Stem Cells For Stroke Patients: A Phase 2a Trial

Mesenchymal Stem Cells For Stroke Patients: A Phase 2a Trial

A recent study published in the journal Stroke revealed Mesenchymal Stem Cell (MSC) therapy as a safe and effective option for stroke patients, and likely for other ischemic conditions.

Ischemic (ischemia) conditions are where there is a lack of oxygen supplied to tissues due to a restriction of blood supply. This could come in the many forms, common ones being a stroke or heart attack. Chronic pain is also considered by many to be an ischemic condition.

StemCells.jpg

Stroke is one of the leading causes of human disability. Many of the current restorative therapies have a short window to see improvements, measured in days to months depending on the severity of the stroke and the health of the patient. Younger patients can recover faster, this is likely due to them having a higher amount of stem cells available to repair. Our natural stores of stem cells decline as we age.

After some preclinical data that supported the safety and efficacy of its MSCs as a restorative therapy to improve outcomes after stroke, a company was granted approval by the FDA to conduct a Phase I/IIa dose escalation trial that examined the effects of a single IV infusion.

This study aimed primarily at the safety of MSC treatments for stroke, but the study also found very significant benefits for the stroke patients. The patients saw improvements in several areas of post-stroke patients even after measuring up to 1 year after the treatment. For those interested in the nitty gritty details you can read them here:

“Improvements across all subjects post-transfusion and for all four secondary endpoints were achieved. Improvements in each index were: Barthel Index (6.8±11.4 points, p=0.002); in NIHSS (-1.25±1.7 points, p<0.001); Mini Mental Status Exam (1.8±2.8 points, p<0.001); and Geriatric Depression Scale (-1.6±3.8 points, p=0.015). At baseline 11.4% (4/35 subjects) had Barthel Index=95-100 (favorable outcome); at 6-months, 27.3% (9/33); by 12-months, 35.5% (11/31).”

The Barthel scale is an ordinal scale used to measure performance in activities of daily living, the NIHSS (The National Institutes of Health Stroke Scale), is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke, the Mini-Mental State Exam is a questionnaire that is used extensively in clinical and research settings to measure cognitive impairment, and the Geriatric Depression Scale is a screening tool used to identify depression in older adults.

These are very promising results! One day we may see MSCs as first-line medicines in ER rooms for strokes and heart attacks. While we’re excited to see more research with MSCs, we think the dosages used were a little low. Understandingly in research they want to assess safety first. In our experience treating hundreds of patients we’ve seen MSC and other regenerative therapies as very safe.

 Take a look at Ted Marek’s testimonial after his astonishing recovery from heart failure with MSC therapy (also like the video and subscribe to get more updated health videos) https://www.youtube.com/watch?v=TwSUU8tjPbA

 

For more info on how MSC can help you or a loved one call Innate Healthcare at 602.603.3118 or schedule a free exam and consult here: https://innatehealthcare.org/schedule